Literature DB >> 217870

The fate of cytoplasmic vanadium. Implications on (NA,K)-ATPase inhibition.

L C Cantley, P Aisen.   

Abstract

The fate of vanadate (+5 oxidation state of vanadium) taken up by the red cell was studied using EPR spectroscopy. The appearance of an EPR signal indicated that most of the cytoplasmic vanadate is reduced to the +4 oxidation state with axial symmetry characteristic of vanadyl ions. The signal at 23 degrees C was characteristic of an immobilized system indicating that the vanadyl ions in the cytoplasm are associated with a large molecule. [48V]Vanadium eluted with hemoglobin when the lysate from Na3[48V[O4-treated red cells was passed through a Sephadex G-100 column and rabbit anti-human hemoglobin serum caused a hemoglobin-specific precipitation of 48V when added to the red cell lysate. Both results indicate that hemoglobin is the protein which binds cytoplasmic vanadyl ions. However, neither sodium vanadate nor vanadyl sulfate bound to purified hemoglobin in vitro. Finally, transient kinetics of vanadyl sulfate interaction with the sodium-and potassium-stimulated adenosine triphosphatase showed that the +4 oxidation state of vanadium is less effective than the +5 oxidation state in inhibiting this enzyme. These results indicate that oxidation-reduction reactions in the cytoplasm are capable of relieving vanadate inhibition of cation transport.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 217870

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Is vanadate reduced by thiols under biological conditions? Changing the redox potential of V(V)/V(IV) by complexation in aqueous solution.

Authors:  Debbie C Crans; Boyan Zhang; Ernestas Gaidamauskas; Anastasios D Keramidas; Gail R Willsky; Chris R Roberts
Journal:  Inorg Chem       Date:  2010-05-03       Impact factor: 5.165

2.  Insulin-like actions of vanadate are mediated in an insulin-receptor-independent manner via non-receptor protein tyrosine kinases and protein phosphotyrosine phosphatases.

Authors:  Y Shechter; J Li; J Meyerovitch; D Gefel; R Bruck; G Elberg; D S Miller; A Shisheva
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

3.  Vanadium chemistry and biochemistry of relevance for use of vanadium compounds as antidiabetic agents.

Authors:  D C Crans; M Mahroof-Tahir; A D Keramidas
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

4.  Protective effect of vanadate on oxyradical-induced changes in isolated perfused heart.

Authors:  T Matsubara; S Musat-Marcu; H P Misra; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

5.  Insulin-like effects of vanadate on glucose uptake and on maturation in Xenopus laevis oocytes.

Authors:  P Hainaut; S Giorgetti; A Kowalski; E Van Obberghen
Journal:  Cell Regul       Date:  1991-04

6.  Influence of vanadate on glycolysis, intracellular sodium, and pH in perfused rat hearts.

Authors:  C F Geraldes; M M Castro; A D Sherry; R Ramasamy
Journal:  Mol Cell Biochem       Date:  1997-05       Impact factor: 3.396

7.  NADH-dependent polyvanadate reduction by microsomes.

Authors:  M S Patole; C K Kurup; T Ramasarma
Journal:  Mol Cell Biochem       Date:  1987-06       Impact factor: 3.396

8.  Significance of NADH-vanadate-oxidoreductase of cardiac and erythrocyte cell membranes.

Authors:  E Erdmann; K Werdan; W Krawietz; M Lebuhn; S Christl
Journal:  Basic Res Cardiol       Date:  1980 May-Jun       Impact factor: 17.165

Review 9.  Metals and breast cancer.

Authors:  Celia Byrne; Shailaja D Divekar; Geoffrey B Storchan; Daniela A Parodi; Mary Beth Martin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-01-22       Impact factor: 2.673

10.  Antimicrobial, insect sterilizing and ovicidal activity of some oxo-vanadium(IV) and oxo-vanadium(V) complexes.

Authors:  S Datta; P Banerjee; R D Banerjee; G M Sarkar; S K Saha; K Dey; R K Maiti; S K Sen; J K Bhar
Journal:  Agents Actions       Date:  1982-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.